Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

New agents for treating neurological disorders disclosed in recent patents

Sep. 23, 2008

EMEA recommends orphan drug designation for AX-200 in spinal cord injury

Sep. 23, 2008

Avigen completes multicenter AV-650 phase IIb spasticity trial in MS

Sep. 23, 2008

AMT and Amgen enter license agreement to develop gene therapy for PD

Sep. 23, 2008

Merck Serono completes enrollment in REFLEX phase III trial of Rebif in MS

Sep. 23, 2008

Memory and Roche expand R-3487/MEM-3454 development program

Sep. 23, 2008

Ovation acquires U.S. rights to Xenazine for chorea associated with HD

Sep. 23, 2008

Omeros and The Parkinson's Institute sign collaboration to evaluate a molecular target in PD

Sep. 23, 2008

Pharmacopeia identifies new lead compound for advancement in alliance with GSK

Sep. 23, 2008

LY-450139 meets efficacy and safety endpoints in Alzheimer's disease phase II study

Sep. 23, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...